Q2 2021 Results - Reimagining Medicine
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
CRM
IHD
Neuroscience
Oncology
Ophthalmology
Respiratory
Sandoz Biopharmaceuticals
Global Health
Abbreviations
VAY736 - BAFF-R inhibitor
Study
Indication
Phase
Patients
Primary Outcome
Measures
NCT03217422 AMBER (CVAY736B2201)
Autoimmune hepatitis
Phase 2
80
Alanine aminotransferase (ALT) normalization
Arms Intervention
VAY736
Placebo control with conversion to active VAY736
Autoimmune hepatitis patients with incomplete response or intolerant to standard
treatment of care
Target Patients
Read-out Milesstone(s)
2026
Publication
TBD
85 Investor Relations | Q2 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation